Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled expertise are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across two sites with three distinct technology platforms designed to meet the evolving demands of our clients and partners.

External Links


ArrantaBio mRNA Vaccine Overview
ArrantaBio mRNA Vaccine Overview

Team Members


Michael Wourms

Senior Vice President, Nucleic Acids Division


Traci Kyes

VP of Commercial Operations


David Stevens

President and Chief Operating Officer